-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 CwyqePf16V9I1IBNMymuL9HjqT77NUEauVIIK/TxajCsG0CumAnJwjw1y/SBx4au
 2zjXcAVPPDirqDXv/5Db4g==

<SEC-DOCUMENT>0000950144-07-005953.txt : 20070625
<SEC-HEADER>0000950144-07-005953.hdr.sgml : 20070625
<ACCEPTANCE-DATETIME>20070622182613
ACCESSION NUMBER:		0000950144-07-005953
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20070621
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20070625
DATE AS OF CHANGE:		20070622

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Geovax Labs, Inc.
		CENTRAL INDEX KEY:			0000832489
		STANDARD INDUSTRIAL CLASSIFICATION:	COMPUTER & OFFICE EQUIPMENT [3570]
		IRS NUMBER:				870455038
		STATE OF INCORPORATION:			IL
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-52091
		FILM NUMBER:		07937422

	BUSINESS ADDRESS:	
		STREET 1:		1256 BRIARCLIFF ROAD N.E.
		STREET 2:		EMTECH BIO SUITE 500
		CITY:			ATLANTA
		STATE:			2Q
		ZIP:			30306
		BUSINESS PHONE:		404 727-0971

	MAIL ADDRESS:	
		STREET 1:		1256 BRIARCLIFF ROAD N.E.
		STREET 2:		EMTECH BIO SUITE 500
		CITY:			ATLANTA
		STATE:			2Q
		ZIP:			30306

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DAUPHIN TECHNOLOGY INC
		DATE OF NAME CHANGE:	19940826

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SUCCESSO INC
		DATE OF NAME CHANGE:	19910410
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>g08034e8vk.htm
<DESCRIPTION>GEOVAX LABS, INC.
<TEXT>
<HTML>
<HEAD>
<TITLE>GEOVAX LABS, INC.</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><IMG src="g08034g0803400.gif" alt="(GEOVAX LOGO)">
</DIV>


<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>








<DIV align="center" style="font-size: 14pt; margin-top: 12pt"><B>SECURITIES AND EXCHANGE COMMISSION</B>
</DIV>

<DIV align="center" style="font-size: 12pt"><B>WASHINGTON, D.C. 20549</B>
</DIV>
<div align="center">
<DIV style="font-size: 3pt; margin-top: 12pt; width: 26%; border-top: 1px solid #000000">&nbsp;</DIV>
</div>

<DIV align="center" style="font-size: 18pt; margin-top: 12pt"><B>FORM 8-K</B>
</DIV>
<DIV align="center" style="font-size: 12pt; margin-top: 12pt"><B>CURRENT REPORT<BR>
Pursuant to Section&nbsp;13 or 15(d) of the<BR>
Securities Exchange Act of 1934</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>Date of report (Date of earliest event reported): June&nbsp;21, 2007</B></DIV>
<div align="center">
<DIV style="font-size: 3pt; margin-top: 12pt; width: 26%; border-top: 1px solid #000000">&nbsp;</DIV>
</div>

<DIV align="center" style="font-size: 24pt; margin-top: 12pt"><B>GEOVAX LABS, INC.</B>
</DIV>

<DIV align="center" style="font-size: 10pt"><B>(Exact name of registrant as specified in Charter)</B></DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="31%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="31%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="31%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><B>Illinois<BR>
(State or other jurisdiction of <BR>
incorporation or organization)</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>000-52091<BR>
(Commission File No.)</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>87-0455038<BR>
(IRS Employee Identification No.)</B></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>1256 Briarcliff Road N.E.<BR>
Emtech Bio Suite&nbsp;500<BR>
Atlanta, Georgia 30306<BR>
(Address of Principal Executive Offices)</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>(404)&nbsp;727-0971<BR>
(Issuer Telephone number)</B>

</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the Registrant under any of the following provisions (see General
Instruction A.2 below).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT face="Wingdings">&#111;</FONT> Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT face="Wingdings">&#111;</FONT> Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR240.14a-12)
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT face="Wingdings">&#111;</FONT> Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT face="Wingdings">&#111;</FONT>
Pre-commencement communications pursuant to Rule&nbsp;13e-4&#169; under the Exchange Act (17 CFR 240.13(e)-4(c))
</DIV>


<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>









<P align="right" style="font-size: 10pt"><!-- Folio --> &nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Helvetica',Arial,san-serif">

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><IMG src="g08034g0803400.gif" alt="(GEOVAX LOGO)">
</DIV>





<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This Form 8-K and other reports filed by GeoVax Labs, Inc. (the &#147;registrant&#148;) from time
to time with the Securities and Exchange Commission (collectively the &#147;Filings&#148;) contain forward
looking statements and information that are based upon beliefs of, and information currently
available to, the registrant&#146;s management as well as estimates and assumptions made by the
registrant&#146;s management. When used in the Filings the words &#147;anticipate&#148;, &#147;believe&#148;, &#147;estimate&#148;,
&#147;expect&#148;, &#147;future&#148;, &#147;intend&#148;, &#147;plan&#148; or the negative if these terms and similar expressions as they
relate to the registrant or the registrant&#146;s management identify forward looking statements. Such
statements reflect the current view of the registrant with respect to future events and are subject
to risks, uncertainties, assumptions and other factors relating to the registrant&#146;s industry,
operations and results of operations and any businesses that may be acquired by the registrant.
Should one or more of these risks or uncertainties materialize, or should the underlying
assumptions prove incorrect, actual results may differ significantly from those anticipated,
believed, estimated, expected, intended or planned.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Item&nbsp;8.01 Other Events</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On June&nbsp;21, 2007 we issued a press release related to the engagement of Althea Technologies,
Inc. as contract manufacturer for our HIV-1 DNA (AIDS)&nbsp;vaccine. A copy of the press release is
attached to this Current Report.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Item&nbsp;9.01 Financial Statements and Exhibits</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exhibit&nbsp;99 Press Release
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>SIGNATURES</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly
caused this Current Report to be signed on its behalf by the undersigned hereunto duly authorized.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Dated: June&nbsp;22, 2007
</DIV>


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">GEOVAX LABS, INC.<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/&nbsp;Mark W. Reynolds</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Mark W. Reynolds&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Chief Financial Officer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>


<P align="right" style="font-size: 10pt"><!-- Folio --> 2 of 4<!-- /Folio -->
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>g08034exv99.htm
<DESCRIPTION>EX-99 PRESS RELEASE
<TEXT>
<HTML>
<HEAD>
<TITLE>EX-99 PRESS RELEASE</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>



<DIV style="font-family: 'Helvetica',Arial,san-serif">

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><IMG src="g08034g0803400.gif" alt="(GEOVAX LOGO)">
</DIV>


<DIV align="right" style="font-size: 10pt; margin-top: 12pt">Exhibit&nbsp;99
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><U>AT THE COMPANY</U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Donald Hildebrand / Jennifer Nelms<BR>
(404)&nbsp;727-0971

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">FOR IMMEDIATE RELEASE<BR>
21 JUNE 2007

</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">GeoVax Contracts Althea Technologies for Phase 2 AIDS Vaccine Production
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">ATLANTA, Ga., 21 June&nbsp;2007 &#150; GeoVax Labs, Inc. (OTC BB: GOVX), an Atlanta based biotechnology
company, announced it engaged Althea Technologies, Inc., San Diego, CA, as contract manufacturer
for its HIV-1 DNA (AIDS)&nbsp;vaccine. This vaccine will be utilized in GeoVax&#146;s advanced Phase 2 human
trials planned for early 2008.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">GeoVax AIDS vaccines are designed to prevent development of Acquired Immunodeficiency Disease
(AIDS)&nbsp;caused by the virus known as HIV-1 by vaccinating individuals prior to AIDS virus infection.
The vaccine regimen employs a &#147;prime-boost strategy.&#148; Trial participants are administered GeoVax
HIV-1 DNA vaccine which &#147;primes&#148; the immune system followed by GeoVax&#146;s HIV-1 MVA (Modified
Vaccinia Virus) boost. Both vaccines deliver over 50% of the AIDS virus components but can&#146;t cause
AIDS. Safety and immunological results from earlier and ongoing human trials are very encouraging
thus supporting planned acceleration of large scale Phase 2 clinical studies.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Summary of Human Trial Results
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Ongoing GeoVax preventive HIV/AIDS vaccine human trials indicated:
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><b>&#149;</b></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Very acceptable safety profiles in 1/10<SUP style="font-size: 85%; vertical-align: text-top">th</SUP> dose trials started April&nbsp;2006</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><b>&#149;</b></TD>
    <TD width="1%">&nbsp;</TD>
    <TD> 1/10<SUP style="font-size: 85%; vertical-align: text-top">th</SUP> dose of vaccine stimulates potentially protective anti-HIV immune
responses in up to 100% of vaccine recipients</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><b>&#149;</b></TD>
    <TD width="1%">&nbsp;</TD>
    <TD> Highly acceptable safety profiles in ongoing full dose trial started September&nbsp;2006</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><b>&#149;</b></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Full doses of GeoVax vaccine stimulate promising immune responses (complete data not
available.)</TD>
</TR>

</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">In ongoing full dose trials, excellent safety data was demonstrated in recipient volunteers. This
trial enrolled 36 volunteers with 30 receiving GeoVax AIDS vaccines and 6 receiving placebo. Trial
enrollment was completed May&nbsp;25, 2007.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">GeoVax chose Althea to manufacture its DNA vaccine based on its extensive experience in DNA vaccine
production and excellent regulatory compliance history. Althea Technologies is a leading provider
of biotechnology industry contract services.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Cyndi Tolman, Vice-President of GeoVax Labs Inc., commented, &#147;We are very pleased with Althea as
contract manufacturer for our DNA-AIDS vaccines due to their well known expertise in this arena.
Manufacturing of vaccines for GeoVax&#146;s Phase 2 human trials is a very important step forward in our
development plan and demonstrates our confidence in the future success of our AIDS vaccine
program.&#148;
</DIV>
<P align="right" style="font-size: 10pt"><!-- Folio --> 3 of 4<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Helvetica',Arial,san-serif">

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><IMG src="g08034g0803400.gif" alt="(GEOVAX LOGO)">
</DIV>




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Human trials utilizing GeoVax&#146;s IADS vaccines are conducted by the HIV Vaccine Trials Network
(HVTN)&nbsp;based in Seattle, Washington. The HVTN, funded and supported by the National Institutes of
Health, is the largest worldwide clinical trials program devoted to the development and testing of
HIV/AIDS vaccines. Preclinical work enabling development of the clinical evaluation of GeoVax&#146;s DNA
and MVA vaccines was also funded and supported by the NIH and National Institute of Allergy and
Infectious Diseases.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">****************************************
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">About GeoVax Labs, Inc. <I>(www.geovax.com)</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">GeoVax Inc. is an Atlanta, Georgia USA biotechnology company established to develop, license and
commercialize the manufacture and sale of human vaccines for diseases caused by HIV-1 &#091;Human
Immunodeficiency Virus&#093; and other infectious agents. GeoVax&#146;s DNA and Recombinant MVA:
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><b>&#149;</b></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>AIDS vaccines protected 22/23 &#091;96%&#093; non-human primates for over 3<FONT style="font-size: 70%"><SUP>1</SUP></FONT>/<FONT style="font-size: 60%">2</FONT> years post-AIDS virus
infection &#150; 5 of 6 non-vaccinates controls died of AIDS</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><b>&#149;</b></TD>

    <TD width="1%">&nbsp;</TD>
    <TD>HIV-AIDS vaccines were satisfactorily manufactured and tested under GMP/GLP &#150; EMEA &#038; FDA
guidelines</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><b>&#149;</b></TD>
    <TD width="1%">&nbsp;</TD>
    <TD> AIDS-DNA vaccine satisfactory completed Phase I human clinical trials</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><b>&#149;</b></TD>
    <TD width="1%">&nbsp;</TD>
    <TD> GeoVax AIDS vaccines are currently in 2 ongoing human trials with positive immune
responses reported in majority of vaccine recipients with good safety.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><b>&#149;</b></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>2 Additional Phase 1/2 stage human trials with GeoVax AIDS vaccines are planned for July
2007 with a Phase 2 trial being planned for early 2008.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><b>&#149;</b></TD>

    <TD width="1%">&nbsp;</TD>
    <TD>AIDS vaccine technology is protected by 20 issued and filed patent applications</TD>
</TR>

</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">About Althea Technologies, Inc. <I>(www.altheatech.com)</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Althea Technologies, a leading San Diego-based pharmaceutical services firm, provides critical
manufacturing and development services that support researchers worldwide in their advancement of
novel therapies and efforts to apply new genomic information. Althea&#146;s services include cGMP
contract manufacturing of recombinant proteins, DNA-based therapeutics and vaccines, aseptic
filling, and gene quantification using real-time PCR and gene expression analysis under GLP
conditions. Additionally, Althea has introduced new services and technologies for the
identification and development of genetic biomarkers with innovative programs such as the company&#146;s
proprietary eXpress Pathway<SUP style="font-size: 85%; vertical-align: text-top">SM</SUP>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>Safe
Harbor Statement</i></div>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>All statements in this news release that are not statements of historical fact are forward-looking
statements. These statements are based on expectations and assumptions as of the date of this
press release and are subject to numerous risks and uncertainties which could cause actual results
to differ materially from those described in the forward-looking statements. Risks and
uncertainties include, but are not limited to, whether; GeoVax can develop these vaccines with the
desired characteristics in a timely manner, GeoVax&#146;s vaccines will be determined to be safe for use
in humans, GeoVax&#146;s vaccines will be effective in preventing AIDS in humans, the vaccines will
receive the regulatory approvals necessary to be licensed and marketed, GeoVax can raise the
required capital to complete development of its vaccines, there is development of competitive
products that may be more effective or easier to use than GeoVax&#146;s products, and other factors over
which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking
statements, and does not intend to do so. Certain matters</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>discussed in this news release are forward looking statements involving certain risks and
uncertainties including, without limitations, risks detailed in the Companies Securities and
Exchange Commission filings and reports.</I>
</DIV>







<P align="right" style="font-size: 10pt"><!-- Folio --> 4 of 4<!-- /Folio -->
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g08034g0803400.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g08034g0803400.gif
M1TE&.#EA2P$T`.8``*.=LDI%:=S9X<G%TL3`SH-]F,*]RV%:?#@R6LW*U:VI
MNFIC@]72W-'-V.'>Y8V)H4(\8XF$G9J4JQL40[FUQ?W]_7MUD5--<>CFZ[6Q
MP3,L5B(;2-C5WK*MO?7T]O#N\8:!FP8",>[L\%E2=>7BZ.SI[JREN+^ZR?3R
M]1(+.YV8K.KH[61=@%M4>?/Q]"TF4::@M`D$-'=QCB@A3:FCMI>1J8N&H)*-
MI5!*;[.OO[RXQT5`97YXE'5NC?'P\]K8X3TW8)6.I7!KB>/?YOOZ^\;#T.;D
MZF9@@?CX^5]8>E9/<X^*H4U(;)^9KW)LBI60IYF1J/GX^6QFAPL%./CW^4Y'
M;]_;XVUHA=K6WPX(.7ARD!8//W-NC$9"9V]IB,O(U-S8W\_,UW1LBY",HW9M
MD)2-I)"*I./AZ9F/J'!IA\O'T\G"SZ>BMZ";L`T'-G!HC$A!:`8!+_S[_/KY
M^O?V^,S%T?O[^\O(TZ^KOG=OCHB$HW!GB,_+U@8",`<",?___R'Y!```````
M+`````!+`30```?_@'^"@X2%AH>(B8J+C(V.BP\SDBT$CY:7F)F:FYR=GI^@
MH:*=&6Y]?5M%HZNLK:ZOL+&RHE(A?GU*5+.[O+V^O[(>*T,"'`U?`T5%!,S-
M!,IJ7V$<`@XK/I=T$WU^(33`X.'BX[(K'&HG2VDM70@O$REN?O/T]?;W]:=^
M,6XI$R\(=HP04X;"'2O8!!6PA0H%N8<0(TH<Y,!$A`47(+S8$@.?QX\@0WX,
M$6,+E!?<^CQP,;&ERY>AYG#0(:%`DBXS4H@4R<U/EBT3-LS0@``!$`@[DB:%
M``$(`@TO-DS8DJ)C3WQ])I@(<6K*$3\I-#!9`$+""2MV8*I="]-#&`4V_UCL
MF!#CZLY;)3<@"*!D@040#R3`R&%`#1\&6!R4^(`"R1PYA.;,\>!#A!$!#,)\
M(4!!09L@$0I<28)#XX01.%)JM'O+S88=9!5\H<.VMFU>#B@\`&+J[CQN6S0$
M8%$`0)V$Y##4Y=8!PH8L(?NDN#"&`H;;V+-W<@``SA;?\Z:\!D%!@`>U-5+.
M&%0!PY<F!Q#H'+DE`(#KVO/K+X3BAI()OF4%P0T98'&>;1YL,P\/BJR@!@P\
M:-"11QM<\(0#^V7(%@HG\`!!%JS=P\T$2FC100,':J<`0Q,D\(@(!*C`Q0Y;
MV&)/"A#P4`1R&O8X3A@@0)!"B/:@TH43&3``6?^&<AR0$@M+7A)%`RI<`02(
M^601``@N^NAE+Q_@`8&-(*%RP`T\]DC`?#'H\$E_%WQ7Y`QX./3EG:U\P,60
M(860@A0<Z*((=RWL4)112NW011)&M.*#$I*\P`,1CW#!T`Q1?D)$`BSP24\(
M$^Q!*9ZD>C)$$E,0^6D6<`S`B!PVO'!+="^D&8H<0*0DQB,;I-1&*W:<P`*6
MOVW1@YVE)OO($$XHZ%$?4T"PQ`J-9``$F2+%P($K&0S9QPPE-!($5ZB(``L)
M-4!0UV\;%("?LO`BHL`+V-X3PPP`S.%(#5O8%587`"O5%`(3N(&%*W1<<$H*
M)#2"0$])S.(!`.K^YH?_!I7$J[$@*#@1W0896/*$C7VXL0,;B]"!0`.OT&!+
M"&,P8@57?K@A0"\4T%M/`15L#.\*`:B*5Q/F/M+!K'Z\\(4C9Z3("AW]]@$$
M2XJ,T!,0OU1@AJ<A5%&TSWA&@4"]]82@`067<(#EMU%$I$)/32A20JH^20#.
M#T'3`\<'8..9VD<Q0,"W)7,<D5(+3I-3@K=P*-)$2B^T#8X+6MS21PQB]-RW
MCP:LBQ4+0V!"0-1^A#Q1$J>XP?(A5&C`C1L@C$.$#+]-<?/F/;KN40@(,)`)
M[=U<('DGF])0PQ,P?*&Y(ACHH,(3`!#P]1#+C8`(!?2\X/L?<@R@`@@@+*&`
M_Q$8/`"^`A5PL`3X@&%H2!02L!]!&,,G@@-#$"R/NWY(WQ."&IIX6!^RH#]-
M>,`,_<J'209G""O`H7^7J\+V('"*+""+$(:[A11ZQH8)8.MR+2@`/7[U@X?=
M8@8`+,3?_+`%!3@B"KWZ5@'WEYV1C"!Q+P21U#S1`)WA(P0O<%4A0."I(J7@
M!G_`PRU"4`!#)$!!6Y`>',C&+LLI01`8T%T,+%`(&)!K`]1ZQ$)8^"X::J=_
M9=N#)M9@.18<H@@W&(,<YSC'("Q-$%CH%3WJTX4-D&P":R"$!=95,N$@P'-N
M",(?7)>5Q%F`(7"P0M[FL0$<*$$#O:%''Q8P""Q$S?\-`!A$`KR5`I19@@`@
MF@+5S*@=9^7##QG#!!OFP41#C$YH60&@!TP(*ANP3`Y86((>^_""HAF@-X'+
M@;G"!('?I(`/('B9Z0:!DIIE@`OLX@$#>E8"-NCN-RT@!`"6,P$,E8`)W`@!
M%_1E"2OT:@<79.5M>$"D$"Q!$P"@9>P*(0.A_8:+7KS%!NHGB!54,P0/^`,1
M]!B"(QRB!0Q10@-B"($HP<!R,UB#*?H0@E@.P@??[(,;";$`AKS``\`C)@,?
M$88:F4&>^9F#'HO$Q4S4P7(',$0:_'D+',@AAAJP`B).X"U.ZL!&7*"-(3P0
MM,LQP`(]B24%]U&``]#,38?_\`&?^M#$0DRU#P%83A96=XD;^($%HX)I=L)0
M1&<V#!-TV"@$#.$$+3!``'C-JP`BP)`(\&$Y7E"$DRZ'A0)P8PI8/40.:&F#
M,%B.DW^@'C<VX(`9G&("BJA%-R)@"`'(2I.UQ`0,3ZI6_>!AIA;+`PX=MK"T
M"@)M\OK-`TQ`2R0.0@Y%4(%N5:"$GNB@!:?8P.T.\0'+X>`/"LL*'_X@A5/$
MP`1_6,X.%''36T"V$#J@6S=&0-!&H``"&C!`:?=C@&IJ,@;3M(079J4%U\YP
M$`J0K0KHH0)Q)O`>)TA-'S001D1X"P$N."I'>>""J&F@!"*8%1,68;DN'*("
MO9V'_QO0@`D1C,`"[ANO?CZ``PBFX%>7T`%T]G$"1\3W%@]H`RWM-HA)WH,"
MO25FZ!!!A.4$0!#;(.:*NA&S/S1X4%8\Q`"01LS^-N('$(B;AGN4`=2BH@:7
MJ("3;I&$3"7BQ"KIW"VZ*H@=8$4(+G#"PNYX"#7\1@B"@(*-$I@%5?PAQ^M)
MA`B[P6)"8,"$GU*"E1/!!A:\=<D]\@$`BA@""*PV$1Q85^#V;`@L/\`'.MR!
M4O_0A0LDX-*8WM8?V-"3)R3""SU)H0?N>XL1)"2Y,6C4(>1@V5O4E!!)@.1]
MH;N($IB@C(#VT0>>@(!9904$*UT$#685@A&D\,JR_0,]]_]1A4$\X-!_6!PW
M4@!E0SS!6S/0]!^.@*U0"L(`4[C%!+9'"#I8]3<Y)<0-R$D"%7AK`F1]WQ^H
M\-Y<]T@$3<!!;]P`AS9`FQ`5H)UZ9$"`>,(WV0[P5@R4`$`C'V+9?=C`HP?Q
M`1"0SMN":$!O(JYJ0?PM!$!0`'*P\)6K7/</`HA:#/`P;QDP)``.Q^T)<&WO
M4F&`"S.8%0(4$&Q$#-)?$#B`T(=^@&;>P@:",`$A8P"'""SAZ5!_.@RH)0<\
M1_P*-EA`)OMP`4.@LQN*)`0#6CV/&13`!CN8T*?V^0<Z''2D;<]5-UIP,Q<,
M0`)'*+$@[$""K_W!`R0P0KT7L0+_$*37$W(00!'4(-1-8(`\G/@`"4J@.2,8
MX=^AX``(6#X*`;1!`P)E@7@700`\[Z0/,A@$'HA5)ARPA`[W`]P19JCTDM'<
M`=\4T8BY/@BKW>+&A!"!*[,P`PDT?A!#\`,0_@S<%PQ>$2I^*2@,L(%Z8!P3
M\Y6^)G+ETS_PP2>TA@5?VU`!*W`!2J+X01N.H($I("`")^CY1VL`!.V6J0K(
M44,26.^1+9@.!1(`>OD0`PB@9(;@`SL0`GOP7A]0`!Z4#_QF`)85<7-@!=QV
M0LM5"'SP'3/@!12`!(B0!0A@3&Z0!2Z4"4.@!N$""GXT`GQ0!&.P@IG@`"JX
M"7(P)#V@_Q`AX`8R^`HIZ!!!X`=OT`HEH`,@<`$O``</8`!I<0@N0`$1<`!,
M$`!46(56&``7D`."\@=1T"$C<(5@V`-?@P$2L``X$``X(`,P0'.$0`,X<'R'
MH#Y',(4ED@/GD0-?&`!FP`55R`0Y@`@$@`<9A@@S,&Y=%@,M4`(+P`1=T`*F
M\P,@@!I)D`%T0`,L@`,7D`<N8`%O4`)#<`!D,`87H`0``!DDP`.,>`2N0@<1
M<`$!,`)U)@C=P'8*!0-*4&DLEG4/<`%)<`4L-@1IP`-8H`5O(`(.`(H/H`0C
M0`,]XP`%,(HP``*[0@A6L`]*9C4O\`?$R#=T<`5Y\`=%<``@(/\%.'`%5L`#
M.'``0E0#%]`%3&`#V$`!2=`$0I".+(,"(-`#1)`&O08$0G`#7K`]-G`%L`4*
M`F`#(P`!6I`!#E=SB]`%B/4'=1`"2E`"81``/-`"KE$"#M`K,X`#&J`"_90"
M.P`!-U0224026R`K4Q!XUX(#7.`&+R`'+@<!5P`'95`(O1(#93`JT;0!(#`#
M;@!=U1<#&G`$6:`!@M`",1`!/H"2\542.9<%(B`V$;<#4Q`#$S!I?Y`!),$#
M,``#,Q`#:>`",9`"Y^%8`>`"?$6`*6`V$[`-&^!Q1V`!?@0#?^`%)/$.8"4'
MHW1@`5`5?/$54.8`,?`"B34*=,`!`)#_!R!@`/+GD(1P`'Y@-R\P!>2&`B[`
M!'YP3GV``/`5`R'@9G\P`"'@1A$`+1Z``D#@!WQ0.1$`&4P0`V#0:]5F"'P0
M0Q=`!Z@$!.=1`WYP!`F&4(*P$7^@'#@P!Z;I1H8U!1[@`KUF`(^4`@YQ`7$P
M4(20FJ>@#UM``VH0`NGF15`&7'/)`R2Q`G40`T!0-%$@:"%@`W+0!7T``5&0
M`R$P`T;0!'X0,7^0`J0E`7Z`9NHR>K%`!6=@!2+P?/96`#&@!UZ9>BLP`CKA
M7!S@#W@I"!Z3;H*@`B$0-RW@!Z'D`PB0!3YP+1MPHO$P!]GE!H)S"")0"R$`
M&F!QH@!B`4.6_P)8-9L.$%9N(@$A\"LC$`,4)J(I\`<[T`?']0="$)R%X#H0
M@`%&<%030`$2T`=BH"]2X`<4L`(:D`5X*04Q0`9_<#0Y=0,YEQ(6T`!;L`&N
MHD15,`>T\U(GX`?A]`<DX`<XD``A4*>220Y*=TDIT"@EQ0,.D`%9,%=3$`*O
M5E)Q)@@LX`<#8`0;X1`#D`*@V:4YD*DY8#H,H`1FPY6#X`$X.$@LH*DY8`5Y
M$`)),#A@*@8QT'U,F0`DL!'A4@0BV#I9\`U_,"8,,@@B()JV90,AL`$,X')_
MN`(UH@#'I`'F`@%3P#=:$`,V0`!^4`4G(`*']`.S5*<1$`,H$U8-,_](>C`(
M08&5VM:GXD`"9^D'Z18`(6``/@!1<^6D!-```O`$^Z``6%`$H_:LO2D(*G8`
M<G`!,>!I5-``*'`&8#`'2O<"R&($#S```@`#'=$!*A`#54`MU?`'K<EV-@`6
M;N`F5+`%4^`#QS17?Z"?UJ,P"#`$%^L'"34(12":I@,'?5`%42`$^Q4&M9`%
M5@"@2J`O_R`(894!`*"`'W`T4\`!(J0%@I`$?N`B)RH(E+D`1J`OZA("C8.N
M#]$O*8`?S9D";^E0%.`L8_`!(\`0&J`#,3"73X"(^E(YKJ(#VS`%,HD%7'`Y
MW7`$4;(5]!`#4O`''&8+5>%I.D%6%X6D@L#_`'ZP'NMV`932`WZ`=+>4%<0'
MASZZ!3/6+VB&/<!Q+WGI!PQ"K0&`#2>*!6H3`E11,W*@!*4C"!I0I'?:;'_0
M!G6Q`>9B.%/PAUQ+#@R0`,-5`0V@`&I``@EP!H+P`02@`'?`-Q7``!UP`@+P
M`0GP`W]@!`F`'U:0`&&4M`6@`C]0`2M``4'0!/'&/0U@`BJ0`QV'6S;P``3@
M`9O2`)/F`FJ@!E3C`M5KI]PK"-M+-2*@!@.PG(6``0FP/7;`!]F[N!)0!`9L
MO0*0`+2Q`L`K"`G``3VS`AE``<;+,EB0@7_0`+Y3`L<["#]``-O#!3'0J[W;
MPJU@`U!@!030*U>J,!9-0$0S$)DNO,.<H`0C-@%YH*#CD`"I\@(7RL-(_`D?
24`0=D"1LX0,$D`'#-0B!```[
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
